BioNTech (BNTX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$3.1B

Revenue (quarter)

$120.6M

Revenue growth (year over year)

−60.72%

Gross profit (trailing twelve months)

$2.3B

Gross margin

75.59%

Net income (trailing twelve months)

−$1.9B

Net income (quarter)

−$937.1M

Net income growth (year over year)

−105.94%

Net margin

−62.34%

Return on equity

−9.19%

EPS (trailing twelve months)

−$7.69

Book value per share

$80.71

P/E (trailing twelve months)

—

Price to book

1.10

Debt to assets

12.71%

Payout ratio

5.08%

Dividend yield

—

Company profile

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.

• Is BioNTech (BNTX) profitable?

  No. BioNTech reported a net loss of $1.9B over the trailing twelve months.

• How much revenue does BioNTech (BNTX) make?

  BioNTech generated $3.1B in revenue over the trailing twelve months, down 60.72% year over year.

• How do I buy stock in BioNTech (BNTX)?

  BNTX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.